## (19) World Intellectual Property Organization

International Bureau



## <del>) 1849 - 1849 - 194</del>30 - 1840

## (43) International Publication Date 11 March 2004 (11.03.2004)

**PCT** 

## (10) International Publication Number WO 2004/019937 A1

(51) International Patent Classification7: A61K 31/421, 9/14, 45/06

(21) International Application Number:

PCT/IN2003/000294

(22) International Filing Date:

2 September 2003 (02.09.2003)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data: 790/MUM/2002 2 September 2002 (02.09.2002)


- (71) Applicant (for all designated States except US): SUN PHARMACEUTICAL INDUSTRIES LIMITED [IN/IN]; ACME PLAZA, ANDHERI-KURLA ROAD, ANDHERI (EAST), 400059 MUMBAI (IN).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): DHARMAD-HIKARI, Nitin, Bhalachandra [IN/IN]; SUN PHAR-MACEUTICAL ADVANCED RESEARCH CENTER LIMITED, BOMBAY COLLEGE OF PHARMACY

BUILDING, 2ND FLOOR, C.S.T. ROAD, KALINA, SANTACRUZ (EAST), 400098 MUMBAI (IN). MUNGRE, Ashish, Prabhakar [IN/IN]; SUN PHARMACEUTICAL ADVANCED RESEARCH CENTER LIMITED, BOMBAY COLLEGE OF PHARMACY BUILDING, 2ND FLOOR, C.S.T. ROAD, KALINA, SANTACRUZ (EAST), 400098 MUMBAI (IN). ZALA, Yashoraj, Rupsinh [IN/IN]; SUN PHARMACEUTICAL ADVANCED RESEARCH CENTER LIMITED, BOMBAY COLLEGE OF PHARMACY BUILDING, 2ND FLOOR, C.S.T. ROAD, KALINA, SANTACRUZ (EAST), 400098 MUMBAI (IN).

- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),

[Continued on next page]

(54) Title: PHARMACEUTICAL COMPOSITION OF METAXALONE WITH ENHANCED ORAL BIOAVAILABILITY



(57) Abstract: The present invention provides a pharmaceutical composition comprising metaxalone and pharmaceutically acceptable excipients, characterized in that the pharmaceutical composition has enhanced oral bioavailability. The present invention also provides a pharmaceutical composition comprising metaxalone and pharmaceutically acceptable excipients, characterized in that the extent of absorption of metaxalone is independent of whether the composition is administered to the patient with food or on an empty stomach.